A narrative review of the role of Eph receptors in head and neck squamous cell carcinoma

• Published in: Oral diseases Vol. 30; no. 3; pp. 833 - 845
• Main Authors: Al‐Jamaei, Aisha A. H., Subramanyam, Ramadugula V., Helder, Marco N., Forouzanfar, Tymour, Meij, Erik H., Al‐Jamei, Sayida, Visscher, Jan G. A. M.
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.04.2024
• Subjects: Clinical trials; Eph protein; Eph receptors; EphA2 protein; Ephrin-B2 - metabolism; expression; Head & neck cancer; head and neck cancer; Head and neck carcinoma; Head and Neck Neoplasms - metabolism; head and neck squamous cell carcinoma; Humans; Immunosuppression; Kinases; metastasis; Proteins; Radioresistance; Receptor, EphB4 - metabolism; Receptors, Eph Family - metabolism; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - metabolism; targeted therapy; targeted therapy; expression; head and neck cancer; metastasis; Eph receptors; head and neck squamous cell carcinoma
• ISSN: 1354-523X; 1601-0825; 1601-0825
• DOI: 10.1111/odi.14625

Tyrosine kinase receptors (TKR) coordinate a variety of pathological processes in head and neck squamous cell carcinoma (HNSCC), and eventually play a role in patient outcomes. In this review, the role of Eph receptors in HNSCC progression and the possibility of targeting these receptors are illustrated. All relevant studies were identified through a comprehensive search of four electronic databases, including PubMed, Scopus, web of science, and Embase till August 2022. EphA2 and EphB4, along with ephrin‐B2, were the most extensively studied proteins in this family. However, overexpression of EphB4 and its ligand ephrin‐B2 were the only proteins that consistently showed association with a poor outcome, indicating that these proteins might serve as valuable prognostic markers in HNSCC. High expression of EphA3 and EphB4 was found to play a crucial role in radioresistance of HNSCC. EphB4 loss, in particular, was observed to induce an immunosuppression phenotypic HNSCC. Currently, ongoing clinical trials are investigating the benefits of EphB4‐ephrin‐B2 blockade in combination with standard of care treatment in HNSCC. Further efforts are needed to explore the biological role and behavioral complexity of this family of TKR in HNSCC with great attention to avoid heterogeneity of HNSCC subsites.